66 results
F-1
EX-10.7
IMCR
Immunocore Holdings plc
15 Jan 21
Registration statement (foreign)
4:57pm
-contractors
Exhibit G — Co-Commercialization Agreement terms
Exhibit H — Nomination Notices for Initial Targets
Exhibit I — Lilly Good Research Practices … not be deemed to be separate Indications;
Infringement
is defined in Clause 15.3.1;
Initial Targets
means the two (2) Targets identified in the fully
DRS/A
EX-10.6
IMCR
Immunocore Holdings plc
22 Dec 20
Draft registration statement (amended)
12:00am
-contractors
Exhibit G — Co-Commercialization Agreement terms
Exhibit H — Nomination Notices for Initial Targets
Exhibit I — Lilly Good Research Practices … not be deemed to be separate Indications;
Infringement
is defined in Clause 15.3.1;
Initial Targets
means the two (2) Targets identified in the fully
S-8
EX-99.6
IMCR
Immunocore Holdings plc
12 Apr 21
Registration of securities for employees
4:02pm
.
PERFORMANCE TARGETS
If the Directors (with the prior consent of the Granter, where appropriate) so determine, the exercise of an Option shall be conditional … ) imposed under Rule 3(B) (together "the Targets")) PROVIDED THAT no such amendment shall be made unless an event has occurred or events have occurred
F-1
EX-10.5
IMCR
Immunocore Holdings plc
15 Jan 21
Registration statement (foreign)
4:57pm
for a Research Program, reviewing and approving amendments to the Research Plans for its respective Research Program;
(d) discuss new Targets validated … by Immunocore or added to the database of Targets that may be available for nomination as an Exclusive Target;
(e) review proposals for nomination of any
DRS/A
EX-10.4
IMCR
Immunocore Holdings plc
22 Dec 20
Draft registration statement (amended)
12:00am
for a Research Program, reviewing and approving amendments to the Research Plans for its respective Research Program;
(d) discuss new Targets validated … by Immunocore or added to the database of Targets that may be available for nomination as an Exclusive Target;
(e) review proposals for nomination of any
F-1
aagjt1a8svsa5zzly al
15 Jan 21
Registration statement (foreign)
4:57pm
424B4
nq3eori
8 Feb 21
Prospectus supplement with pricing info
8:36am
DRS/A
sa5psre
19 Nov 20
Draft registration statement (amended)
12:00am
DRS
y2tnomqx8 8f45epl940
17 Nov 20
Draft registration statement
12:00am
F-1/A
9ftfb6rm32w ck
1 Feb 21
Registration statement (foreign) (amended)
6:21am
F-1/A
l45xpy0 x1b
3 Feb 21
Registration statement (foreign) (amended)
5:22pm
20-F
svwr6nufshpzbcx4uah
25 Mar 21
Annual report (foreign)
7:01am
DRS/A
EX-10.5
6pao46la704srsutlt6
22 Dec 20
Draft registration statement (amended)
12:00am
F-1
EX-10.6
5uu43vi 2vuups
15 Jan 21
Registration statement (foreign)
4:57pm
6-K
EX-99.1
yn6uik4x8 1uoaqr
11 Jul 22
Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV
4:05pm
6-K
EX-99.3
hs8134fmt6 e2
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
6-K
EX-99.3
gtmgw vt46
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
10-K
jw4fu1uv
28 Feb 24
Annual report
7:33am
6-K
EX-99.1
1oyya8
3 Mar 22
Immunocore Reports Full Year 2021 Financial Results
7:01am